Yeung K S, Meanwell N A, Qiu Z, Hernandez D, Zhang S, McPhee F, Weinheimer S, Clark J M, Janc J W
Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, POBox 5100, Wallingford, CT 06492, USA.
Bioorg Med Chem Lett. 2001 Sep 3;11(17):2355-9. doi: 10.1016/s0960-894x(01)00457-7.
A survey of isosteric replacements of the phosphonoalanine side chain coupled with a process of conformational constraint of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of hepatitis C virus (HCV) NS3 serine protease resulted in the identification of novel series of active compounds with extended side chains. However, Zn(2+)-dependent HCV NS3 inhibition was relatively insensitive to the structural variations examined but dependent on the presence of negatively charged functionality. This result was interpreted in the context of an initial electrostatic interaction between protease and inhibitor that is subsequently consolidated by Zn(2+), with binding facilitated by the featureless active site and proximal regions of the HCV NS3 protein.
对膦酰基丙氨酸侧链的等排取代进行研究,并结合基于双苯并咪唑的、锌(2+)依赖性丙型肝炎病毒(HCV)NS3丝氨酸蛋白酶抑制剂的构象限制过程,结果鉴定出了一系列具有延长侧链的新型活性化合物。然而,锌(2+)依赖性HCV NS3抑制作用对所研究的结构变化相对不敏感,但依赖于带负电荷官能团的存在。在蛋白酶与抑制剂之间最初的静电相互作用的背景下解释了这一结果,该相互作用随后由锌(2+)巩固,HCV NS3蛋白的无特征活性位点和近端区域促进了结合。